BoonHuey Ee – General Manager, Merck Biopharma Taiwan
BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths…
Address: 11F, 80 Linshen North Road, Taipei,Taiwan
Tel: (02)2655-8168
Web: http://www.ibmi.org.tw/client/
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan. Supported by the President of Legislative Yuan, Mr. Wang Jin-Pyng, the predecessor of IBMI began its operation in 1998. In 1999, Mr. Wang took on the post as the chairman and defined the mission of IBMI as ‘Upgrading Biotechnology and Medicine for National Health’. In March 2002, IBMI was officially founded as an organization dedicated to promoting the biotechnology and medicine industry. In June 2005, IBMI convened its first member conference of the second year where the second board of directors and supervisors were elected. The board continued to uphold the ideology and mission of the organization to push forward industrial growth. In May 2009, at the first member conference of the third year the third board of directors and supervisors were elected. Mr. Wang Jin-Pyng was unanimously honored as the founder of IBMI and for his contribution to the biotechnology and medicine industry. Former President of National Taiwan University and the Vice Chairman of IBMI, Dr. Chen Wei-Zhao was elected as chairman of the third board of directors and supervisors to lead IBMI.
The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
From perspective of policy development, at IBMI, it is considered that productive industry policy and market mechanism are essential for assuring the best interest of the state and the public. Innovation-based approaches to developing the emerging industry and market-oriented approaches to commercialization are keys to improving state’s economic competitiveness. Therefore, IBMI intends to assist government and industry in formulating and implementing relevant industrial policies, establishing market mechanism, fostering innovation, and ensuring global competitiveness.
Based on the above considerations, IBMI sets its priority to cause productive partnerships among academia, government, industry and research institutions. Therefore, through promotion and operation of its six functions, i.e., ‘Productive Legislation and Policies’, ‘Certification and Market Mechanism’, ‘Education and Training’, ‘Bioinformatics and Bio-trading’, ‘Advanced and Applied Bio-researches’, and ‘Emerging Business Development’, IBMI strives to develop Taiwan’s biomedical industry, improve the quality of its healthcare system, as well as enhance its overall competitiveness.
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan.The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths…
Taiwan’s biotech sector is growing rapidly and increasingly embracing advanced fields such as precision medicine and AI. However, Johnsee Lee, chairman of the Taiwan Bio Industry Organization warns that the island’s…
Rita Huang, dean of the Office of Research and Development and the director of the TMU Research Center for Cell Therapy and Regeneration Medicine highlights the center’s unique capabilities and…
NYMU President Dr Steve Kuo describes the history of the university and transformative period it is currently undergoing. Dr Kuo shares the university’s key strengths and unique strategy to merge…
Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on…
Shih-Chung Chen, Minister of Health and Welfare of the Republic of China (Taiwan), gives an update on the Ministry’s current directives under the Biomedical Industry Innovation Program to bolster Taiwan’s…
Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two…
Johnsee Lee, chairman of Taiwan Bio Industry Organization, gives an update on the major developments of the country’s biotech environment over recent years, speaking about its new areas of focus,…
Professor Chi-Hung Lin of NCTU discusses the opportunities and hurdles for unveiling smart healthcare in Taiwan. He also assesses Taiwan’s position in the global race for smart healthcare, and how…
Dar-Bin Shieh, deputy minister of science and technology of the Republic of China (Taiwan), gives an overview of Biomedical Industry Innovation Program, enacted to bolster Taiwan’s biomedical and biotechnology sectors…
Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health…
Taiwan’s Minister of Economic Affairs, Jong-Chin Shen, outlines the initiatives implemented by the Ministry to help Taiwan’s industries reinforce their competitive advantage. Minister Shen also goes on to explain the…
See our Cookie Privacy Policy Here